162 related articles for article (PubMed ID: 35657000)
21. Response to mTOR and PI3K inhibitors in enzalutamide-resistant luminal androgen receptor triple-negative breast cancer patient-derived xenografts.
Coussy F; Lavigne M; de Koning L; Botty RE; Nemati F; Naguez A; Bataillon G; Ouine B; Dahmani A; Montaudon E; Painsec P; Chateau-Joubert S; Laetitia F; Larcher T; Vacher S; Chemlali W; Briaux A; Melaabi S; Salomon AV; Guinebretiere JM; Bieche I; Marangoni E
Theranostics; 2020; 10(4):1531-1543. PubMed ID: 32042320
[TBL] [Abstract][Full Text] [Related]
22. Detection of PIK3/AKT pathway in Moroccan population with triple negative breast cancer.
Jouali F; Marchoudi N; Talbi S; Bilal B; El Khasmi M; Rhaissi H; Fekkak J
BMC Cancer; 2018 Sep; 18(1):900. PubMed ID: 30227836
[TBL] [Abstract][Full Text] [Related]
23. Somatic Mutational Profile of High-Grade Serous Ovarian Carcinoma and Triple-Negative Breast Carcinoma in Young and Elderly Patients: Similarities and Divergences.
Serio PAMP; de Lima Pereira GF; Katayama MLH; Roela RA; Maistro S; Folgueira MAAK
Cells; 2021 Dec; 10(12):. PubMed ID: 34944094
[TBL] [Abstract][Full Text] [Related]
24. Characterization of frequently mutated cancer genes in Chinese breast tumors: a comparison of Chinese and TCGA cohorts.
Zhang G; Wang Y; Chen B; Guo L; Cao L; Ren C; Wen L; Li K; Jia M; Li C; Mok H; Chen X; Wei G; Lin J; Zhang Z; Hou T; Han-Zhang H; Liu C; Liu H; Liu J; Balch CM; Meric-Bernstam F; Liao N
Ann Transl Med; 2019 Apr; 7(8):179. PubMed ID: 31168460
[TBL] [Abstract][Full Text] [Related]
25. Tumor mutation burden and
Zhang X; Li J; Yang Q; Wang Y; Li X; Liu Y; Shan B
Ann Transl Med; 2020 Sep; 8(17):1052. PubMed ID: 33145271
[TBL] [Abstract][Full Text] [Related]
26. Co-Expression and Combined Prognostic Value of CSPG4 and PDL1 in
Hu ZY; Zheng C; Yang J; Ding S; Tian C; Xie N; Xue L; Wu M; Fu S; Rao Z; Price MA; McCarthy JB; Ouyang Q; Lin J; Deng X
Front Oncol; 2022; 12():804466. PubMed ID: 35280756
[TBL] [Abstract][Full Text] [Related]
27. Tumor Mutation Burden and Immune Invasion Characteristics in Triple Negative Breast Cancer: Genome High-Throughput Data Analysis.
Gao C; Li H; Liu C; Xu X; Zhuang J; Zhou C; Liu L; Feng F; Sun C
Front Immunol; 2021; 12():650491. PubMed ID: 33968045
[TBL] [Abstract][Full Text] [Related]
28. GATA3 mutations define a unique subtype of luminal-like breast cancer with improved survival.
Jiang YZ; Yu KD; Zuo WJ; Peng WT; Shao ZM
Cancer; 2014 May; 120(9):1329-37. PubMed ID: 24477928
[TBL] [Abstract][Full Text] [Related]
29. A predictor of pathological complete response to neoadjuvant chemotherapy in triple-negative breast cancer patients with the DNA repair genes.
Huang L; Lang GT; Liu Q; Shi JX; Shao ZM; Cao AY
Ann Transl Med; 2021 Feb; 9(4):301. PubMed ID: 33708928
[TBL] [Abstract][Full Text] [Related]
30. Integrative exploration of genomic profiles for triple negative breast cancer identifies potential drug targets.
Wang X; Guda C
Medicine (Baltimore); 2016 Jul; 95(30):e4321. PubMed ID: 27472710
[TBL] [Abstract][Full Text] [Related]
31. Delineation of the Germline and Somatic Mutation Interaction Landscape in Triple-Negative and Non-Triple-Negative Breast Cancer.
Wu J; Mamidi TKK; Zhang L; Hicks C
Int J Genomics; 2020; 2020():2641370. PubMed ID: 32724790
[TBL] [Abstract][Full Text] [Related]
32. Whole-Exome Sequencing Reveals High Mutational Concordance between Primary and Matched Recurrent Triple-Negative Breast Cancers.
Kaur J; Chandrashekar DS; Varga Z; Sobottka B; Janssen E; Gandhi K; Kowalski J; Kiraz U; Varambally S; Aneja R
Genes (Basel); 2023 Aug; 14(9):. PubMed ID: 37761830
[TBL] [Abstract][Full Text] [Related]
33. Patient-derived xenografts of triple-negative breast cancer reproduce molecular features of patient tumors and respond to mTOR inhibition.
Zhang H; Cohen AL; Krishnakumar S; Wapnir IL; Veeriah S; Deng G; Coram MA; Piskun CM; Longacre TA; Herrler M; Frimannsson DO; Telli ML; Dirbas FM; Matin AC; Dairkee SH; Larijani B; Glinsky GV; Bild AH; Jeffrey SS
Breast Cancer Res; 2014 Apr; 16(2):R36. PubMed ID: 24708766
[TBL] [Abstract][Full Text] [Related]
34. Analysis of PIK3CA Mutations and Activation Pathways in Triple Negative Breast Cancer.
Cossu-Rocca P; Orrù S; Muroni MR; Sanges F; Sotgiu G; Ena S; Pira G; Murgia L; Manca A; Uras MG; Sarobba MG; Urru S; De Miglio MR
PLoS One; 2015; 10(11):e0141763. PubMed ID: 26540293
[TBL] [Abstract][Full Text] [Related]
35. PIK3CA mutation confers resistance to chemotherapy in triple-negative breast cancer by inhibiting apoptosis and activating the PI3K/AKT/mTOR signaling pathway.
Hu H; Zhu J; Zhong Y; Geng R; Ji Y; Guan Q; Hong C; Wei Y; Min N; Qi A; Zhang Y; Li X
Ann Transl Med; 2021 Mar; 9(5):410. PubMed ID: 33842631
[TBL] [Abstract][Full Text] [Related]
36. Genetic alterations of triple negative breast cancer (TNBC) in women from Northeastern Mexico.
Uscanga-Perales GI; Santuario-Facio SK; Sanchez-Dominguez CN; Cardona-Huerta S; Muñoz-Maldonado GE; Ruiz-Flores P; Barcenas-Walls JR; Osuna-Rosales LE; Rojas-Martinez A; Gonzalez-Guerrero JF; Valero-Gomez J; Gomez-Macias GS; Barbosa-Quintana A; Barboza-Quintana O; Garza-Guajardo R; Ortiz-Lopez R
Oncol Lett; 2019 Mar; 17(3):3581-3588. PubMed ID: 30867801
[TBL] [Abstract][Full Text] [Related]
37. PIK3CA mutations in Peruvian patients with HER2-amplified and triple negative non-metastatic breast cancers.
Castaneda CA; Lopez-Ilasaca M; Pinto JA; Chirinos-Arias M; Doimi F; Neciosup SP; Rojas KI; Vidaurre T; Balko JM; Arteaga CL; Gomez HL
Hematol Oncol Stem Cell Ther; 2014 Dec; 7(4):142-8. PubMed ID: 25467032
[TBL] [Abstract][Full Text] [Related]
38. The feasibility of circulating tumor DNA analysis as a marker of recurrence in triple-negative breast cancer.
Okazaki S; Sasaki T; Yasuda S; Abe M; Yoshida N; Yoshida R; Ishibashi K; Minami Y; Okumura S; Chiba S; Takei H; Hayashi R; Nagato T; Kobayashi H; Sugitani A; Ono Y; Mizukami Y; Kitada M; Ohsaki Y
Oncol Lett; 2021 May; 21(5):420. PubMed ID: 33841581
[TBL] [Abstract][Full Text] [Related]
39. Addition of triple negativity of breast cancer as an indicator for germline mutations in predisposing genes increases sensitivity of clinical selection criteria.
Hoyer J; Vasileiou G; Uebe S; Wunderle M; Kraus C; Fasching PA; Thiel CT; Hartmann A; Beckmann MW; Lux MP; Reis A
BMC Cancer; 2018 Sep; 18(1):926. PubMed ID: 30257646
[TBL] [Abstract][Full Text] [Related]
40. Predictive Biomarker Profiling of > 6000 Breast Cancer Patients Shows Heterogeneity in TNBC, With Treatment Implications.
Millis SZ; Gatalica Z; Winkler J; Vranic S; Kimbrough J; Reddy S; O'Shaughnessy JA
Clin Breast Cancer; 2015 Dec; 15(6):473-481.e3. PubMed ID: 26051240
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
